Acorda Therapeutics, Inc. (NASDAQ:ACOR) is reporting third quarter earnings results on Tuesday 3rd November 2020, after market close.
The consensus estimates from Thomson Reuters are loss of $ 0.31 per share.
For the full year, analysts predict revenues of $ 119.34 million, while looking forward to loss of $ 1.64 per share.
The Company Outlook
Full Year 2020 topline are forecasted in a range of$ 130.00 million ~ $ 160.00 million
Click Here For More Historical Outlooks Of Acorda Therapeutics, Inc.
Previous Quarter Performance
Acorda Therapeutics, Inc. announced loss for the second quarter of $ 0.35 per share, from the revenue of $ 33.62 million. The quarterly revenues declined 32.83 percent compared with the same quarter last year. The consensus estimates are loss of $ 0.48 per share from $ 27.40 million in revenue. The bottom line results beat street analysts by $ 0.13 or 27.08 percent, at the same time, top line results outshined analysts by $ 6.22 million or 22.70 percent.
Stock Performance
Shares of Acorda Therapeutics, Inc. traded up $ 0.23 or 25.83 percent on Monday, reaching $ 1.10 with volume of 8.22 million shares. Acorda Therapeutics, Inc. has traded high as $ 1.12 and has cracked $ 0.87 on the downward trend
The closing price of $ 1.10, representing a 107.14 % increase from the 52 week low of $ 0.42 and a 68.71 % decrease over the 52 week high of $ 2.78.
The company has a market capital of $ 52.77 million and is part of the Healthcare sector and Biotechnology industry.
Conference Call
Acorda Therapeutics, Inc. will be hosting a conference call at 4:30 PM eastern time on 3rd November 2020, to discuss its 3Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.acorda.com
Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); and Selincro, an orally administered drug for the treatment of alcohol dependence in Europe. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas.
